SOURCE: INVO Bioscience, Inc

January 12, 2010 08:00 ET

INVO Bioscience, Inc. Announces Symposium on the INVO Technology

BEVERLY, MA--(Marketwire - January 12, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced that the annual Salvador Society of Endoscopy and Reproduction Symposium is being dedicated to the INVO technology, in honor of Dr. Ranoux, in San Salvador on January 30, 2010. The Symposium will have Dr. Ranoux presenting the INVO procedure along with the results of the recently completed 50 person INVO study performed by the CECOLFES clinic in Bogota, Colombia. As well, Dr. Elkin Lucena of CECOLFES and Dr. Rene Frydman, a well known French Reproductive Endocrinologist and advocate of the INVO procedure, will be speaking on the INVO Procedure. OB/Gyns and IVF physicians from throughout Latin America will be in attendance to learn about the INVO technology. The conference will enable INVO Bioscience to reach additional physicians and clinics throughout Latin America.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Contact:
    Kathleen Karloff
    INVO Bioscience, Inc.
    978-878-9505 x 504
    Email Contact